Arbutus Biopharma Corp expected to post a loss of 11 cents a share - Earnings Preview

Arbutus Biopharma

03/11/2023 14:52

* Arbutus Biopharma Corp  ABUS.OQ   ABUS.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Warminster Pennsylvania-based  company is expected to
report
 a 20.2% decrease in revenue to $4.752 million from $5.95
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Arbutus Biopharma
Corp is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Arbutus
Biopharma
Corp is $4​, above​ its last closing price of $1.81. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.11      -0.10     Beat    10.9
 Mar. 31 2023  -0.14       -0.14      -0.10     Beat    26.5
 Dec. 31 2022  -0.13       -0.13      -0.14     Missed  -5.2​
 Sep. 30 2022  -0.13       -0.13      -0.12     Beat    6.3
 ​​Jun.        -0.12       -0.13      -0.10     Beat    20.6
 30 2022                                                
 Mar. 31 2022  -0.15       -0.16      -0.11     Beat    31.3​
 Dec. 31 2021  -0.19       -0.19      -0.15     Beat    21.1
 Sep. 30 2021  -0.24       -0.24      -0.24     Met     -0.8
 This summary was machine generated November 3 at 14:52 GMT.  All
figures in US dollars  unless otherwise stated